New perspectives for treatment of pulmonary embolism.


Subcutaneous low-molecular-weight heparins (LMWHs) have been shown to be as safe and effective as intravenous unfractionated heparin (UFH) for the initial treatment of patients with deep vein thrombosis and acute symptomatic pulmonary embolism. In comparison with UFH, LMWHs have a longer half-life, greater bioavailability and more predictable antithrombotic… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics